Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015
Open Access
- 1 April 2018
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 178 (4) , 567-569
Abstract
The Centers for Medicare and Medicaid Services (CMS) Part D program provided prescription drug coverage to 40.8 million beneficiaries in 2016.1 Between 2012 and 2015, the program spent $397.8 billion on prescription drugs, while beneficiary out-of-pocket costs totaled $54.6 billion.2 Over the next decade, spending is projected to increase by 77%.3 Several large pharmacy benefit managers (PBMs) have attempted to limit prescription drug costs by using formulary drug exclusion lists, but the extent to which these apply to Medicare Part D plans is unknown. These lists identify brand-name medications that are ineligible for coverage and specify either covered brand-name and/or lower-cost, generic substitutes. We estimated potential Part D program and beneficiary savings on medications excluded by PBMs for which generic substitutes are available.Keywords
This publication has 1 reference indexed in Scilit:
- Estimation of Potential Savings Through Therapeutic SubstitutionJAMA Internal Medicine, 2016